Background: Genome-wide association studies have identified over 170 common breast cancer susceptibility variants, many of them with differential associations by estrogen receptor (ER).
Introduction
Breast cancer represents a heterogenous group of diseases with different molecular and clinical features [1] . Clinical assessment of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and histological grade are routinely determined to inform treatment strategies and prognostication [2] . Combined, these tumor features define five intrinsic-like subtypes (i.e. luminal A-like, luminal B/HER2-negative-like, luminal B-like, HER2-enriched-like, and basal-like/triple negative) that are correlated with intrinsic subtypes defined by gene expression panels [2] . Most known breast cancer risk or protective factors are related to luminal or hormone receptor (ER or PR; HR) positive tumors, whereas less is known about the etiology of triple-negative (TN) tumors, an aggressive subtype [3, 4] .
Breast cancer genome-wide association studies (GWAS) have identified over 170 susceptibility single nucleotide polymorphisms (SNPs), of which many are differentially associated with ER-positive than ER-negative disease [5] . These include 20 SNPs that primarily predispose to ER-negative or TN disease [6, 7] . However, few studies have evaluated SNP associations with other tumor features, or simultaneously studied multiple, correlated tumor markers to identify source(s) of etiologic heterogeneity [6, [8] [9] [10] [11] [12] . We recently developed a twostage polytomous logistic regression method that efficiently characterizes etiologic heterogeneity while accounting for tumor marker correlations and missing tumor data [13] .
This method can help describe complex relationships between susceptibility variants and multiple tumor features, helping to clarify breast cancer subtype etiologies and increasing the power to generate more accurate risk estimates between susceptibility variants and less common subtypes.
In this report, we applied this novel methodology to a large study population from the Breast Cancer Association Consortium (BCAC) to characterize risk associations of 178 known breast cancer susceptibility SNPs with tumor subtypes defined by ER, PR, HER2 and tumor grade.
Methods

Study Population and Genotyping
The study population and genotyping are described in previous publications [5, 6] and in the Supplemental Methods. We included invasive cases and controls from 81 BCAC studies with genotyping data from two Illumina genome-wide custom arrays, the iCOGS and OncoArray (106,571 cases (OncoArray: 71,788; iCOGS: 34,783) and 95,762 controls (OncoArray: 58,134; iCOGS: 37,628); Supplemental Table 1 ). We evaluated 178 susceptibility SNPs that were identified in or replicated by prior BCAC analyses [5, 6] . Genotypes for the SNPs marking the 178 susceptibility loci were determined by genotyping with the iCOGS and the OncoArray arrays and imputation to the 1000 Genomes Project (Phase 3) reference panel.
Statistical Analysis
The statistical methods, including a detailed discussion of the two-stage polytomous logistic regression, are provided in the Supplemental Methods and elsewhere [13] . Briefly, we identified SNPs showing evidence for heterogeneity by using a mixed-effects two-stage polytomous model to evaluate a global heterogeneity test that assesses whether a SNP's case-control risk-estimates vary by at least one of the underlying tumor characteristics. We accounted for multiple testing of the global heterogeneity test using a false discovery rate (FDR) <0.05 under the Benjamini-Hochberg procedure [14] . Among SNPs with evidence for heterogeneity, we used a fixed-effects two-stage model to evaluate a case-case marker-specific tumor heterogeneity test, which identifies the specific tumor marker(s) contributing to the observed heterogeneity, adjusting for the other tumor markers in the model. Marker-specific P<0.05 was considered statistically significant. Our primary analyses evaluated heterogeneity by ER, PR, HER2 and grade. As a secondary analysis, we fit an extended model with an additional term for TN status to test for differences between TN vs non-TN subtypes. The two-stage model implements an efficient expectation-maximization algorithm [15] to essentially perform iterative "imputation" of missing tumor characteristics [13] . We fit an additional two-stage model to estimate case-control ORs and 95% confidence intervals (CI) between the SNPs and five intrinsic-like subtypes defined by combinations of ER, PR, HER2 and grade (see separately, adjusting for the first 10 principal components for ancestry-informative SNPs, and then meta-analyzed the results. We used Euclidean distance in cluster analyses to help describe results and identify common heterogeneity patterns.
Results
The mean (SD) ages at diagnosis (cases) and enrollment (controls) were 56.6 (12.2) and 56.4 (12.2) years, respectively. Eighty-one percent of tumors were ER-positive, 68% PRpositive, 83% HER2-negative and 69% grade 1 or 2 ( Table 1 ; Supplemental Table 1 ). The most common intrinsic-like subtype was luminal A-like (59%), followed by TN (13%), luminal B/HER2-negative-like (12%), Luminal B-like (12%) and HER2-enriched-like (5%; Table 1 ).
The two-stage models including terms for ER, PR, HER2 and grade, simultaneously adjusting for each other, identified 85 of 178 SNPs (47.7%) with evidence for heterogeneity by at least one tumor feature (FDR<5%). ER and grade most often contributed to the observed heterogeneity (45 and 34 SNPs respectively had case-case marker-specific P<0.05), and 30 SNPs were significantly associated with more than one tumor characteristic ( Case-control comparisons for the 85 SNPs with evidence for global heterogeneity identified four main clusters of SNPs according to the p-values for risk associations with each subtype (Figure 2 and Supplemental Figure 2 ). Sixty-five SNPs in cluster 1 (n=3 SNPs) and cluster 4 (n=62 SNPs) showed the strongest evidence for associations with risk for luminal-like subtypes, cluster 2 (n=5 SNPs) was associated with risk for all subtypes at varying strengths and cluster 3 (n=15 SNPs) with stronger evidence for TN or non-luminal subtype associations.
Supplemental Table 2 shows the associations between all 178 SNPs and the intrinsic-like subtypes. and rs74911261 (OR (95% CI)=0.93 (0.90-0.96), P=2.71x10 -11 ), were significantly associated (P<0.05) only with TN disease (Figures 2-3; Supplemental Figure 2) . In the extended model these five SNPs were associated with TN status (PTN<0.05; Supplemental Figure 3) . The remaining 10 SNPs in case-control comparisons were all associated with TN disease (P<0.05; (Supplemental Figure 1) .
Besides rs11374964 and rs74911261, SNPs in this cluster were not HR-negative or TN-specific SNPs as they were also associated with luminal-like subtypes. Three SNPs showed weak associations with luminal A-like disease (OR (95% CI)=0.98 (0.97 to 1.00); P=0.039 for rs67397200; OR (95% CI)=1.02 (1.00 to 1.03); P=0.024 for rs6678914; and OR (95% CI)=1.02 (1.00 to 1.04); P=0.02 for rs4577244) in an opposite direction to their associations with TN disease (OR (95% CI)=0.93 (0.91 to 0.96); P=1.07x10 -4 for rs6678914 and OR (95% CI)=0.90 (0.86 to 0.93); P=2.99x10 -9 for rs4577244; Figures 2-3; Supplemental Figure 2 ). Figure 2 and Supplemental Figures 2,4) . In case-case comparisons these five SNPs were associated with grade (Pgrade=2.32x10 -02 for rs62355902, Pgrade=1.74x10 -13 for rs75915166, Pgrade=2.14x10 -12 for rs554219, Pgrade=2.20x10 -12 for rs11249433 and Pgrade=2.47x10 -06 for rs10941679) and with at least one other tumor marker (Supplemental Figure 1) . Eighteen Figure 5 shows case-control associations by tumor grade for 12 SNPs associated exclusively with grade in case-case comparisons (Pgrade<0.05). rs11571833, rs17426269 and rs11820646 showed stronger evidence for predisposing to risk of high-grade subtypes, and the remaining SNPs showed stronger evidence for predisposing to risk of low-grade subtypes.
Discussion
We found compelling evidence that about half of the investigated breast cancer susceptibility loci (85 of 178 SNPs) predispose to tumors of different characteristics. We SNPs in the loci for FGFR2 (rs35054928 and rs2981578) [16, 17] and 8q24.21 (rs13281615) [16] that were associated with luminal-like and HER2-enriched-like subtypes. rs4784227 located near TOX3 [16, 18] and rs62355902 located in a MAP3K1 [16] regulatory element, were associated with risk of all five subtypes. Of the five SNPs found associated in opposite directions with luminal A-like and TN disease, we previously reported rs6678914 and rs4577244 to have opposite effects between ER-negative and ER-positive tumors [6] . rs17879961 (I157T), a likely causal [19] mis-sense variant located in a CHEK2 functional domain that reduces or abolishes substrate binding [20] , was previously reported to have opposite directions of effects on lung adenocarcinoma and lung squamous cell carcinoma and for lung cancer between smokers and non-smokers [21, 22] . However, further studies are required to follow-up and clarify the mechanisms for these apparent cross-over effects.
In prior ER-negative GWAS we identified 20 SNPs that predispose to ER-negative disease, of which five SNPs were only or most strongly associated with risk of TN disease (rs4245739, rs10069690, rs74911261, rs11374964, and rs67397200) [6, 7] . We further confirmed these five SNPs to be most strongly associated with TN disease and that they were associated with TN status in the extended model. The remaining previously identified 15 SNPs all showed associations with risk of HR-negative disease, and for all but four SNPs (rs17350191, rs200648189, rs6569648, and rs322144) evidence of global heterogeneity was observed.
Among the SNPs in cluster 3, rs3215401 was the only SNP that was not identified in a prior ERnegative GWAS [6, 7] . rs3215401 was identified in a fine-mapping analysis of TERT and, consistent with our findings, reported to be most strongly associated with ER-negative disease but was also associated with ER-positive disease [23] .
Little is known regarding PR and HER2 as sources of etiologic heterogeneity independent of ER or TN status. Of the four SNPs significantly associated only with PR, rs10759243 [5, 24] , rs11199914 [5] and rs72749841 [5] were previously found primarily associated with risk of ERpositive disease, and rs10816625 was found to be associated with risk of ER-positive/PRpositive tumors, but not other ER/PR combinations [11] . rs10995201 was the only variant found to be solely associated with HER2 status, although the evidence was not strong, requiring further confirmation. Previously rs10995201 showed no evidence of being associated with ER status [25] . Among all SNPs found with PR or HER2 associations, few have been investigated for PR or HER2 heterogeneity while adjusting for ER [8] [9] [10] [11] [12] . We previously reported rs10941679 to be associated with PR-status, independent of ER, and also with grade [9] . We also found suggestive evidence of PR-specific heterogeneity for 16q12-rs3803662 [12] , which is in high LD (r 2 = 0.78) with rs4784227 (TOX3), which was strongly associated with PR status. Our findings for rs2747652 are also consistent with a prior BCAC fine-mapping analysis across the ESR1 locus, which found rs2747652 to be associated with risk of the HER2-enriched subtype and high grade independent of ER [8] . rs2747652 overlaps an enhancer region and is associated with reduced ESR1 and CCDC170 expression [8] .
Histologic grade is a composite of multiple tumor characteristics including mitotic count, nuclear pleomorphism, and degree of tubule or gland formation [26] . Among the 12 SNPs identified with evidence of heterogeneity by grade only, rs17426269, rs11820646, and rs11571833 were found most strongly associated with grade 3 disease. rs11571833 lies in the BRCA2 coding region and produces a truncated form of the protein [27] and has been shown to be associated with both risk of TN disease and risk of serous ovarian tumors, both of which tend to be high-grade [28] . To our knowledge, rs17426269 and rs11820646 have not been investigated in relation to grade heterogeneity. The remaining 9 SNPs were all more strongly associated with grade 1 or grade 2 disease. Five of these SNPs were previously reported to be associated primarily with ER-positive disease [5, 29, 30] , highlighting the importance of accounting for multiple tumor characteristics to better illuminate heterogeneity sources.
A major strength of our study is our large sample size of over 100,000 breast cancer cases with tumor marker information, and a similar number of controls, making this the largest, most comprehensive breast cancer heterogeneity investigation. Our application of the novel two-stage polytomous logistic regression enabled adjusting for multiple, correlated tumor markers and accounting for missing tumor marker data. This is a more powerful and efficient modeling strategy for identifying heterogeneity sources among highly correlated tumor markers, compared with standard polytomous logistic regression. However, we identified 17
SNPs with evidence of heterogeneity for which we did not identify specific tumor characteristic(s) contributing to observed heterogeneity. This is likely explained by the fact that the fixed-effects models evaluating specific tumor markers as heterogeneity sources were less statistically powerful compared with the mixed-effects models that evaluated for evidence of global heterogeneity [13] . Our approach to cluster SNPs helped describe common heterogeneity patterns; however, these clusters should not be interpreted as strictly defined categories. Our study was limited by investigating only ER, PR, HER2, and grade as heterogeneity sources and future studies with more detailed tumor characterization could reveal additional etiologic heterogeneity sources.
In summary, our findings provide insights into the complex etiologic heterogeneity patterns of common breast cancer susceptibility loci. These findings may inform fine-mapping and functional analyses to identify the underlying causal variants, clarifying biological mechanisms that drive genetic predisposition to breast cancer subtypes. Moreover, these analyses provide precise estimates of relative risk for different intrinsic-like subtypes that could improve the discriminatory accuracy of subtype-specific polygenic risk scores [31] . 
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